search
Back to results

New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women

Primary Purpose

PreTerm Birth

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
QUIPP
Sponsored by
Hospital Clinic of Barcelona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for PreTerm Birth focused on measuring Preterm Birth, Asymptomatic high-risk women, QUIPP, Quantitative fetal fibronectin, Cervical length

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Age ≥ 18 years old
  • Asymptomatic singleton pregnancies, with at least one of the following: Previous spontaneous preterm delivery or a preterm premature rupture of membranes ≤ 346 weeks of gestation, Previous spontaneous second trimester miscarriage, Previous surgery on uterine cervix, Incidental finding of cervical length less than 25mm, Uterine malformations.
  • Able to sign informed consent form.

Exclusion Criteria:

  • Multiple pregnancies.
  • Congenital, chromosomal abnormalities or stillbirth in current pregnancy.
  • No patient consent to participate in the study
  • Women with an obstetrical history of iatrogenic preterm birth indicated for maternal or fetal conditions.
  • Symptomatic high-risk women or preterm prelabor rupture of membranes in current pregnancy.
  • Pregnant women with an indication of prophylactic cervical cerclage due to her own obstetrical history.
  • Pregnant women with a short cervix detected by ultrasound and with an indication to perform a cervical cerclage, prior to study inclusion.

Sites / Locations

  • Hospital Sant Joan de DéuRecruiting
  • Hospital Clínic Barcelona ( Maternitat)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention group: QUIPP tool arm

Control group: no QUIPP tool arm

Arm Description

In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.

Women will be managed according to current clinical practice.

Outcomes

Primary Outcome Measures

Spontaneous preterm birth before 34.0 and 37.0 weeks of gestation
Delivery < 34.0 and <37.0 weeks of gestation ( Yes/No )

Secondary Outcome Measures

Gestational age at delivery
Weeks and days at the moment of delivery
Hospital admission due to sPTB or PPROM
Number of hospital admission due to a spontaneous preterm labor or a preterm premature rupture of membranes
Emergency department visits due to uterine contractions
Number of emergency department visits
Clinical chorioamnionitis
Fever ( >37.8 ºC) and maternal tachycardia ( >100 beats per minute) and /or fetal tachycardia ( >160 beats per minute) and/or maternal leukocytosis ( >15000 leukocites/mm3) and/or uterine contractions and/or malodorous leukorrhea
Maternal mortality
Maternal death (Yes/No)
5 min APGAR score <7
APGAR test less than 7 at the 5 minuts after birth
umbilical artery pH at delivery <7.1
pH artery value less than 7.1
NCIU admission
Admission in a neonatal intensive care unit ( Yes/No)
Need for respiratory support
Administration of respiratory support during the NCIU stay.
Respiratory distress syndrome
Breathing disorder ( Yes /No)
Intraventricular haemorrhage
Severe intraventricular haemorrhage grade III/IV
Necrotizing enterocolitis
Intestinal necrosis in the newborn ( Yes/No)
Neonatal sepsis
Blood infection of the newborn (Yes/No)
Neonatal mortality
neonatal death

Full Information

First Posted
November 29, 2016
Last Updated
February 19, 2017
Sponsor
Hospital Clinic of Barcelona
search

1. Study Identification

Unique Protocol Identification Number
NCT03062020
Brief Title
New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women
Official Title
New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
November 16, 2016 (Actual)
Primary Completion Date
November 2020 (Anticipated)
Study Completion Date
June 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital Clinic of Barcelona

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The QUIPP tool integrates information of obstetrical history, quantitative fetal fibronectin (qfFN) and cervical length to predict the risk of sPTB in asymptomatic high-risk women. The aim of this study is to evaluate the QUIPP tool in our setting in order to optimize the management of women at high risk for sPTB and to validate in a randomized clinical trial, whether the use of QUIPP improves efficiently the management of our asymptomatic high-risk women when it is compared with the current clinical management. Design: Randomized controlled trial. Inclusion criteria: Asymptomatic singleton pregnancies 18,0-22,6 weeks at high-risk for sPTB. Sample size: According to a non-inferiority analysis, 129 pregnant women will be needed for each arm. Methodology: Patient selection and who consent to participate in the study will be randomized into two arms: a) Intervention group: QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit. b) Control group: Women will be managed according to current clinical practice. Main Outcome: sPTB <34,0 and <37,0 weeks of gestation. Secondary Outcomes: Pregnancy outcomes and a neonatal composite morbidity. Expected Results: Perinatal outcomes are similar in the intervention and control group although the intervention group using the QUIPP tool required less medical resources.
Detailed Description
Preterm birth (PTB) is a leading cause of perinatal morbidity and mortality. Women at high-risk of preterm birth are those with a previous spontaneous preterm birth (sPTB) or preterm premature rupture of membranes before 35 weeks of gestation, uterine malformation, surgery on uterine cervix or a short cervical length; these women have a global risk of PTB about 30% but still 75%-85% of these women will deliver at term without any intervention. The availability of a specialized Preterm Birth Prevention Clinic (PBPC) is relevant for the management of these high-risk pregnant women and it results in a reduction in the risk of recurrent sPTB, pregnancy prolongation and a reduction in the rate of major neonatal morbidity. However, it implies higher outpatient care costs as well as trained personnel and intensive follow-up management even for those women not destined to deliver preterm QUIPP is a free smartphone application that integrates the obstetrical history of high-risk women, the cervical length and the value of quantitative fetal fibronectin to predict the risk of preterm birth. QUIPP will determinate the risk of preterm birth in these high-risk women. Patients will be randomized in two groups: Intervention group (QUIPP tool arm): QUIPP tool is applied and patients with a high-risk result will be follow-up in a high-risk unit (PBPC) and patients with a low-risk value will be managed in a low-risk unit. Control group (no QUIPP tool arm): current management in a PBPC will be applied. The use of QUIPP will allow determining which asymptomatic pregnancies with risk factors for sPTB will deliver preterm. Furthermore, we expect to provide the non-specialized clinician with an objective, useful, accurate and efficient tool to manage these women with same pregnancy and neonatal outcomes and using less resource.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreTerm Birth
Keywords
Preterm Birth, Asymptomatic high-risk women, QUIPP, Quantitative fetal fibronectin, Cervical length

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
258 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group: QUIPP tool arm
Arm Type
Experimental
Arm Description
In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
Arm Title
Control group: no QUIPP tool arm
Arm Type
No Intervention
Arm Description
Women will be managed according to current clinical practice.
Intervention Type
Device
Intervention Name(s)
QUIPP
Intervention Description
Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
Primary Outcome Measure Information:
Title
Spontaneous preterm birth before 34.0 and 37.0 weeks of gestation
Description
Delivery < 34.0 and <37.0 weeks of gestation ( Yes/No )
Time Frame
3.5 years
Secondary Outcome Measure Information:
Title
Gestational age at delivery
Description
Weeks and days at the moment of delivery
Time Frame
3,5 years
Title
Hospital admission due to sPTB or PPROM
Description
Number of hospital admission due to a spontaneous preterm labor or a preterm premature rupture of membranes
Time Frame
3.5 years
Title
Emergency department visits due to uterine contractions
Description
Number of emergency department visits
Time Frame
3.5 years
Title
Clinical chorioamnionitis
Description
Fever ( >37.8 ºC) and maternal tachycardia ( >100 beats per minute) and /or fetal tachycardia ( >160 beats per minute) and/or maternal leukocytosis ( >15000 leukocites/mm3) and/or uterine contractions and/or malodorous leukorrhea
Time Frame
3.5 years
Title
Maternal mortality
Description
Maternal death (Yes/No)
Time Frame
3.5 years
Title
5 min APGAR score <7
Description
APGAR test less than 7 at the 5 minuts after birth
Time Frame
3.5 years
Title
umbilical artery pH at delivery <7.1
Description
pH artery value less than 7.1
Time Frame
3.5 years
Title
NCIU admission
Description
Admission in a neonatal intensive care unit ( Yes/No)
Time Frame
3.5 years
Title
Need for respiratory support
Description
Administration of respiratory support during the NCIU stay.
Time Frame
3.5 years
Title
Respiratory distress syndrome
Description
Breathing disorder ( Yes /No)
Time Frame
3.5 years
Title
Intraventricular haemorrhage
Description
Severe intraventricular haemorrhage grade III/IV
Time Frame
3.5 years
Title
Necrotizing enterocolitis
Description
Intestinal necrosis in the newborn ( Yes/No)
Time Frame
3.5 years
Title
Neonatal sepsis
Description
Blood infection of the newborn (Yes/No)
Time Frame
3.5 years
Title
Neonatal mortality
Description
neonatal death
Time Frame
3.5 years

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old Asymptomatic singleton pregnancies, with at least one of the following: Previous spontaneous preterm delivery or a preterm premature rupture of membranes ≤ 346 weeks of gestation, Previous spontaneous second trimester miscarriage, Previous surgery on uterine cervix, Incidental finding of cervical length less than 25mm, Uterine malformations. Able to sign informed consent form. Exclusion Criteria: Multiple pregnancies. Congenital, chromosomal abnormalities or stillbirth in current pregnancy. No patient consent to participate in the study Women with an obstetrical history of iatrogenic preterm birth indicated for maternal or fetal conditions. Symptomatic high-risk women or preterm prelabor rupture of membranes in current pregnancy. Pregnant women with an indication of prophylactic cervical cerclage due to her own obstetrical history. Pregnant women with a short cervix detected by ultrasound and with an indication to perform a cervical cerclage, prior to study inclusion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Núria Lorente, M.D
Phone
+34932532100
Email
nlorente@sjdhospitalbarcelona.org
First Name & Middle Initial & Last Name or Official Title & Degree
Montse Palacio, M.D, Ph.D
Phone
+3493 227 9946
Ext
9904
Email
MPALACIO@clinic.cat
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Núria Lorente, M.D
Organizational Affiliation
BCNatal | Barcelona Center for Maternal Fetal and Neonatal Medicine | Hospital Clínic - Hospital Sant Joan de Déu
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Sant Joan de Déu
City
Esplugues de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08950
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Núria Lorente, M.D
Phone
+34932532100
Email
nlorente@sjdbarcelonahospital.org
First Name & Middle Initial & Last Name & Degree
Núria Lorente, M.D
First Name & Middle Initial & Last Name & Degree
Sílvia Ferrero, M.D, Ph.D
First Name & Middle Initial & Last Name & Degree
Rosalia Pascal, Resident
Facility Name
Hospital Clínic Barcelona ( Maternitat)
City
Barcelona
ZIP/Postal Code
08028
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Montse Palacio, M.D, Ph.D
Phone
+34932279946
Ext
9904
Email
MPALACIO@clinic.cat
First Name & Middle Initial & Last Name & Degree
Teresa Cobo, M.D, Ph. D
First Name & Middle Initial & Last Name & Degree
Federico Migliorelli, M.D
First Name & Middle Initial & Last Name & Degree
Núria Baños, M.D

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19254585
Citation
Kurtzman J, Chandiramani M, Briley A, Poston L, Das A, Shennan A. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery. Am J Obstet Gynecol. 2009 Mar;200(3):263.e1-6. doi: 10.1016/j.ajog.2009.01.018.
Results Reference
background
PubMed Identifier
25932845
Citation
Abbott DS, Hezelgrave NL, Seed PT, Norman JE, David AL, Bennett PR, Girling JC, Chandirimani M, Stock SJ, Carter J, Cate R, Kurtzman J, Tribe RM, Shennan AH. Quantitative fetal fibronectin to predict preterm birth in asymptomatic women at high risk. Obstet Gynecol. 2015 May;125(5):1168-1176. doi: 10.1097/AOG.0000000000000754.
Results Reference
background
PubMed Identifier
25846437
Citation
Kuhrt K, Smout E, Hezelgrave N, Seed PT, Carter J, Shennan AH. Development and validation of a tool incorporating cervical length and quantitative fetal fibronectin to predict spontaneous preterm birth in asymptomatic high-risk women. Ultrasound Obstet Gynecol. 2016 Jan;47(1):104-9. doi: 10.1002/uog.14865.
Results Reference
background

Learn more about this trial

New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women

We'll reach out to this number within 24 hrs